BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16709306)

  • 1. Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.
    Rodríguez-Leal CM; González-Corralejo C; Candel FJ; Salavert M;
    Rev Esp Quimioter; 2024 Jun; 37(3):221-251. PubMed ID: 38436606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.
    Fujitani S; Sun HY; Yu VL; Weingarten JA
    Chest; 2011 Apr; 139(4):909-919. PubMed ID: 21467058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia.
    Zhao X; Wu JF; Xiu QY; Wang C; Zhang DP; Huang JA; Xie CM; Sun SH; Lv XJ; Si B; Xiao ZK; Zhang YY
    Diagn Microbiol Infect Dis; 2014 Oct; 80(2):141-7. PubMed ID: 25130297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
    Anderson VR; Perry CM
    Drugs; 2008; 68(4):535-65. PubMed ID: 18318569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin for the treatment of respiratory tract infections.
    Torres A; Liapikou A
    Expert Opin Pharmacother; 2012 Jun; 13(8):1203-12. PubMed ID: 22594848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
    Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
    Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones.
    Wang S; Chan SY; Deng Y; Khoo BL; Chua SL
    J Adv Res; 2024 Jan; 55():33-44. PubMed ID: 36822389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.
    Zilberberg MD; Chen J; Mody SH; Ramsey AM; Shorr AF
    BMC Pulm Med; 2010 Aug; 10():45. PubMed ID: 20796312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment of pseudomonal infections in the elderly.
    Pappas G; Saplaoura K; Falagas ME
    Drugs Aging; 2009; 26(5):363-79. PubMed ID: 19552489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
    West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
    Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin in the treatment of community-acquired pneumonia.
    Noreddin AM; Elkhatib WF
    Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.